PURPOSEAs part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in patients with cyclin D–CDK4/6 ...

The expression of cyclin D1 is upregulated in various cancer cells by diverse mechanisms, such as increases in mRNA levels, the promotion of the translation by mammalian target of rapamycin ...

For about a decade, scientists have recognized that many cases of hereditary breast cancer result from a mutation of a specific gene called BRCA1, which, in its normal state, helps keep tumor ...

Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

One major focus of Dr. Diehl’s research concerns the mechanisms whereby growth-signaling pathways regulate the cyclin D/CDK4/6 kinases and from this, the identification of therapeutic vulnerabilities.

Cyclin D1 promotes nuclear DNA synthesis through phosphorylation and inactivation of the pRb tumor suppressor. Herein, cyclin D deficiency increased mitochondrial size and activity that was rescued by ...

In mammals, D-type cyclin-associated kinases mainly regulate the G1/S transition by phosphorylating the retinoblastoma (Rb) protein. We previously demonstrated that in tobacco, cyclin D (Nicta; ...

Researchers investigated COVID-19-triggered changes in the levels of cyclins and cyclin-dependent kinases inside host cells.

One major focus of Dr. Diehl’s research concerns the mechanisms whereby growth-signaling pathways regulate the cyclin D/CDK4/6 kinases and from this, the identification of therapeutic vulnerabilities.

The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.

The Emerman lab performed a latency HIV-CRISPR screen and identified Cyclin T1 as a host factor required for reversal of HIV latency ...